- Enhance Celgene’s Inflammation & Immunology (I&I) portfolio.
- Further diversifies the Company’s revenue beginning in 2019.
- Build upon Celgene’s growing expertise in inflammatory bowel disease (IBD) by the addition of Ozanimod, a novel orally administered drug that has shown efficacy in the improvement of patients with ulcerative colitis.
This week Celgene Corporation, a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation, announced that it has signed an agreement in which it will acquire Receptos, Inc. (NASDAQ: RCPT) a biopharmaceutical company that specializes in the development of therapeutic candidates for the treatment of immune and metabolic diseases. According to the companies, the acquisition will: